KIT and gastrointestinal stromal tumor: In the clinic, imatinib has revolutionized the treatment of advanced GIST [1]; however, even patients who initially respond to this treatment develop resistance over time, which most commonly is caused by the development of secondary mutations in KIT [3,19].